Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Soulagel is a topical herbal gel developed for the management of acute musculoskeletal pain and soft tissue injuries. The formulation is composed of a synergistic blend of natural active ingredients, including menthol, camphor, and essential oils such as eucalyptus, rosemary, and lavender. It functions as a topical analgesic and anti-inflammatory agent, providing a cooling sensation and localized pain relief by targeting transient receptor potential (TRP) channels. Soulagel has been evaluated in clinical trials, notably by researchers at the Université de Monastir in Tunisia, as a potential alternative to topical non-steroidal anti-inflammatory drugs (NSAIDs) like piroxicam for patients presenting with acute extremity pain.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Soulagel.